Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 17%
Buy 42%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is positioned favorably due to its promising clinical-stage product candidates, particularly BT1718 and BT5528, which exhibit potential advantages in efficacy and tolerability compared to current market competitors like Padcev. Positive feedback from key opinion leaders indicates a strong preference for the Zele + Keytruda combination therapy, which could lead to significant treatment switching opportunities if its efficacy aligns with expectations. Additionally, the company’s innovative approach to drug design, particularly in the radiopharmaceutical space, has garnered investor interest, anticipating substantial growth in tumor targeting capabilities and overall safety profiles.

Bears say

Bicycle Therapeutics PLC has experienced significant stock pressure, with shares declining 45% year-to-date, primarily attributed to investor concerns over the efficacy and safety profile of its product candidate, Zelenectide, particularly in comparison to existing therapies like Padcev. The uncertainty related to Zelenectide’s competitive edge, combined with a confirmed overall response rate (ORR) of only 50% when used with Keytruda, further exacerbates the negative sentiment surrounding the stock. Additionally, there are risks associated with potential challenges in intellectual property and a shift towards competing next-generation therapies, which could adversely affect the company's market positioning and platform valuation.

BCYC has been analyzed by 12 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 42% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 12 analysts, BCYC has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.